<DOC>
	<DOCNO>NCT01892202</DOCNO>
	<brief_summary>This multicenter observational study evaluate efficacy safety Mircera ( methoxy polyethylene glycol-epoetin beta ) patient chronic kidney disease dialysis routine clinical practice . Eligible patient treat Mircera chronic renal anemia accord standard care line current local label follow 6 month .</brief_summary>
	<brief_title>A Non-Interventional Study Mircera ( Methoxy Polyethylene Glycol-Epoetin Beta ) Patients With Chronic Kidney Disease Not Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Adult patient , 18 65 year age inclusive Patients chronic kidney disease Stage IIIIV dialysis Hb &lt; 10 g/dL ( correction anemia ) Hb 1012 g/dL receive ESA ( maintenance Hb level ) Adequate iron status judge treat physician Hypersensitivity recombinant human erythropoietin , polyethylene glycol constituent study medication Significant acute chronic bleed Hemoglobinopathies ( e.g . homozygous sicklecell disease , thalassemia type ) Active malignant disease last five year ( except nonmelanoma skin cancer ) Uncontrolled symptomatic secondary hyperparathyroidism Epileptic seizure last 6 month Poorly control hypertension ( sit blood pressure &gt; 170/100 mmHG ) Myocardial infarction stroke , severe unstable CAD Severe liver disease previous 6 month Congestive heart failure NYHA Class IIIIV Diagnosis suspicion pure red cell aplasia ( PRCA ) Planned elective surgery study period ( except cataract surgery vascular access surgery ) Transfusion red blood cell previous 2 month Pregnant woman Any contraindication Mircera</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>